PH1: A Novel Molecule for Advanced Prostate Cancer
/in Antibody-Drug Conjugate, Preclinical Research/by MaxCancer’s Hidden Brake: How a Hormone Shields Tumors from Immune Attack
/in Immunotherapy, Preclinical Research/by MaxPlant Virus-Based Cancer Immunotherapy: A New Frontier in Fighting Cancer
/in Oncolytic, Preclinical Research/by MaxAPVO442: A Promising Preclinical Candidate in the Fight Against Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxA Seattle-based biotech, is stepping up with APVO442, a promising preclinical bispecific antibody aimed at transforming prostate cancer treatment by unleashing the body’s immune system against tumors with greater precision and fewer side effects. Built on proprietary ADAPTIR-FLEX platform, APVO442 is designed to target prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer […]
A New Genetic Engineering Tool To Revolutionize Cancer Therapies
/in CRISPR, Preclinical Research/by MaxKCL-HO-1i: A Novel HO-1 Inhibitor Targeting Tumor-Associated Macrophages
/in Preclinical Research/by MaxNew Bacterial Therapy Destroys Tumors in Immunocompromised Animal Models
/in Oncolytic, Preclinical Research/by MaxUPDATE 2: More Data About ATNM-400 Antibody Radioconjugate Therapy
/in Antibody Radioconjugate, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Not All Patients Benefit Equally: New Score Refines Cabazitaxel Use April 25, 2026
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
- Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC April 21, 2026